ArticleFrontiers in pharmacology2022
Honokiol improves depression-like behaviors in rats by HIF-1α- VEGF signaling pathway activation.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- Efficacy of empagliflozin as adjunctive therapy to citalopram in major depressive disorder: a randomized double-blind, placebo-controlled clinical trial.BMC psychiatry · 2024Trial
- Honokiol and Magnolol Exert an Anti-Inflammatory Effect by Inhibiting JAK2/STAT3/IL17 Signalling in a Rat Model of Ulcerative Colitis: A Combination of Bioinformatics and Experimental Study.Journal of cellular and molecular medicine · 2026Article
- A classic traditional chinese medicine formula for depression: mechanistic insights from phytochemical constituents and multitarget pathways.Psychopharmacology · 2025Article
- Antibacterial, Photoprotective, Anti-Inflammatory, and Selected Anticancer Properties of Honokiol Extracted from Plants of the GenusInternational journal of molecular sciences · 2025Review
- 2-Methoxyestradiol attenuates lung injury induced by chronic intermittent hypoxia via inhibiting the HIF1-α/SLC7A11 pathway.Scientific reports · 2025Article
- Schaftoside Reduces Depression- and Anxiogenic-like Behaviors in Mice Depression Models.Brain sciences · 2025Article
- Important functions and molecular mechanisms of aquaporins family on respiratory diseases: potential translational values.Journal of Cancer · 2024Review
- The therapeutic potential of traditional Chinese medicine in depression: focused on the modulation of neuroplasticity.Frontiers in pharmacology · 2024Review
- Neuropharmacological potential of honokiol and its derivatives from Chinese herb Magnolia species: understandings from therapeutic viewpoint.Chinese medicine · 2023Review
- Depression and Its Phytopharmacotherapy-A Narrative Review.International journal of molecular sciences · 2023Review
- A network medicine-based approach to explore the relationship between depression and inflammation.Frontiers in psychiatry · 2023Article
- Dissecting the molecular mechanisms underlying the antidepressant activities of herbal medicines through the comprehensive review of the recent literatures.Frontiers in psychiatry · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing evidence indicates that the pathogenesis of depression is closely linked to impairments in neuronal synaptic plasticity. Honokiol, a biologically active substance extracted from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.